Table 4.
Adverse effects of atezolizumab and bevacizumab (65 patients).
| Adverse effects | Any grade, n (%) | ≥ Grade 3, n (%) | |
|---|---|---|---|
| Adverse effects from any cause | 19 (29.2) | 7 (10.7) | |
| IRAE | 9 (13.8) | 3 (4.6) | |
| Discontinuation of experimental drug | Atezolizumab and Bevacizumab | – | 4 (6.1) |
| Bevacizumab only | – | 3 (4.6) | |
| Bleeding-related events caused by bevacizumab | 3 (4.6) | 1 (1.5) | |
| Diarrhoea | 3 (4.6) | – | |
| Hypertension | 3 (4.6) | – | |
| Fatigue | 3 (4.6) | – | |
| Pruritus | 3 (4.6) | – | |
| Rash | 2 (3) | – | |
| Proteinuria | 2 (3) | 1 (1.5) | |
| Platelet count decline | 2 (3) | – | |
| Aspartate aminotransferase increase | 1 (1.5) | – | |
| Immune thyroiditis | 7 (10.7) | – | |
| Immune colitis | 1 (1.5) | 1 | |
| Hypophysitis | – | 1 (1.5) | |
| Nephritis | 1 (1.5) | 1 (1.5) | |
Bold values indicate statistical significance.
IRAE = immune related adverse event.